NeuroPace to Host Investor Day on January 28th in New York City
NeuroPace to Host Investor Day on January 28th in New York City
MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will host an Investor Day from 9:00 a.m. – 12:00 p.m. ET on Tuesday, January 28, 2025 in New York City.
加利福尼亞州山景城，2024年12月12日（環球新聞通訊）—— NeuroPace, Inc.（納斯達克：NPCE）是一家專注於改變癲癇患者生活的器械公司，今天宣佈公司將在2025年1月28日星期二東部時間上午9:00至中午12:00在紐約市舉辦投資者日。
The Investor Day will provide an update on NeuroPace's vision for its unique RNS technology and will highlight the Company's plans including presentations from management discussing NeuroPace's recent results, future plans, and market, product and clinical development strategies for the RNS System. The Company will also host guest speakers, including clinical key opinion leaders and an RNS patient who will provide their personal experience with the RNS System and its impact on their epilepsy.
投資者日將提供關於NeuroPace獨特RNS技術的願景更新，並將重點介紹公司計劃，包括管理層的演示，討論NeuroPace的近期業績、未來計劃以及RNS系統的市場、產品和臨床發展戰略。公司還將邀請嘉賓演講，包括臨床關鍵意見領袖和一位RNS患者，他們將分享個人經歷以及RNS系統對他們癲癇的影響。
Use the link below to register for the event:
請使用以下鏈接註冊活動：
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
關於NeuroPace, Inc.
NeuroPace總部位於加利福尼亞州山景城，是一家專注於通過減少或消除嚴重癲癇發作的發生來改變癲癇患者生活的器械公司。其新穎且獨特的RNS系統是首個也是唯一一個商業化可用的腦響應平台，能夠在癲癇發作源處提供個性化的實時治療。該平台能夠爲生活在藥物抵抗癲癇中的患者提供更好的護理標準，並有可能爲大量 suffering from 其他腦部疾病的患者提供更個性化的解決方案和改善的結果。
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
投資者聯繫人：
傑里米·費弗
董事總經理
LifeSci顧問
jfeffer@lifesciadvisors.com
譯文內容由第三人軟體翻譯。
